Literature DB >> 11504493

Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs.

Stephen P. Ackland1, Godefridus J. Peters.   

Abstract

Thymidine phosphorylase (TP) is an angiogenic enzyme present in normal tissues. Increased levels are found in many tumors, in stromal cells, tumor cells or both. High tumor TP levels may confer a poor prognosis. Cytokines (including interferons), tissue hypoxia and low pH increase TP levels. The influence of tumor TP on fluoropyrimidine toxicity is variable, but capecitabine is a prodrug of fluorouracil that requires activation by TP and hence may have a higher therapeutic index than other fluoropyrimidines. Folate-based thymidylate synthase inhibitors may also be more effective in tumors with a high TP because of increased degradation of endogenous thymidine. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11504493     DOI: 10.1054/drup.1999.0089

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  16 in total

1.  Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil.

Authors:  Agnieszka Kotlarz; Małgorzata Przybyszewska; Paweł Swoboda; Joanna Miłoszewska; Monika Anna Grygorowicz; Andrzej Kutner; Sergiusz Markowicz
Journal:  Tumour Biol       Date:  2015-10-28

2.  Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.

Authors:  Xueming Jiang; Zhixiang Zhang; Na Zhao; Xianghui He; Hao Guo
Journal:  Visc Med       Date:  2016-03-18

Review 3.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Authors:  Wataru Ichikawa
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

4.  Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance.

Authors:  Michal Stark; Eran E Bram; Martin Akerman; Yael Mandel-Gutfreund; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

Review 5.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

6.  Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.

Authors:  I V Bijnsdorp; F Capriotti; F A E Kruyt; N Losekoot; M Fukushima; A W Griffioen; V L Thijssen; G J Peters
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

7.  Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro.

Authors:  I V Bijnsdorp; Godefridus J Peters
Journal:  Cancer Drug Resist       Date:  2021-05-24

8.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

Authors:  J Nakano; C Huang; D Liu; D Masuya; T Nakashima; H Yokomise; M Ueno; H Wada; M Fukushima
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

9.  Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.

Authors:  Kazumi Uchida; Peter V Danenberg; Kathleen D Danenberg; Jean L Grem
Journal:  BMC Cancer       Date:  2008-12-23       Impact factor: 4.430

10.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.